Fallas SM

Idioma: Español
Referencias bibliográficas: 22
Paginas: 427-429
Archivo PDF: 265.70 Kb.

RESUMEN

La infección por Helicobacter pylori ha sido reconocida como uno de los factores de riesgo más importantes en el desarrollo del cáncer gástrico. Debido a esto, la erradicación de H. pylori ha sido propuesta como una estrategia primaria preventiva para disminuir la incidencia del cáncer gástrico. El objetivo de este artículo es evaluar la evidencia disponible sobre la eficacia de la erradicación de H. pylori en la prevención del cáncer gástrico.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Blanchard T, Drakes M, Czinn S: Helicobacter infection: pathogenesis. Curr Opin Gastroenterol. 2004; 20:10-15.

2. Chiba T, Marusawa H, Seno H, Watanabe N: Mechanism for Gastric Cancer Development by Helicobacter pylori Infection. J Gastroenterol Hepatol. 2008; 23(8):1175-1181.

3. Chiba T, Seno H, Marusawa H, Wakatsuki Y, Okazaki K: Host factors are important in determining clinical outcomes of Helicobacter pylori infection. J. Gastroenterol. 2006; 41: 1-9.

4. Correa P: Is gastric cancer preventable? Gut 2004; 53:1217-1219.

5. Fischbach L, Evans L: Meta-analysis: The Effect of Antibiotic Resistance Status on the Efficacy of Triple and Quadruple First-line Therapies for Helicobacter pylori. Aliment Pharmacol Ther. 2007; 26(3):343-357.

6. Fuccio L, Zagari R, Minardi M, Bazzoli F: Systematic Review: Helicobacter Pylori Eradication for the Prevention of Gastric Cancer. Aliment Pharmacol Ther. 2007; 25(2):133-141.

7. Graham D, Shiotani A: The time to eradicate gastric cancer is now. Gut. 2005; 54: 735-738.

8. Ito M, Haruma K, Kamada T, et al: Helicobacter pylori eradication therapy improves atrophic gastritis and intestinal metaplasia: a 5-year prospective study of patients with atrophic gastritis. Aliment Pharmacol Ther. 2002; 16: 1449–1456.

9. Jodlowski T, Lam S, Ashby C: Emerging Therapies for the Treatment of Helicobacter pylori Infections. Ann Pharmacother. 2008; 42(11):1621-1639.

10. Kamada T, Hata J, Sugiu K et al: Clinical features of gastric cancer discovered after successful eradication of Helicobacter pylori: results from a 9-year prospective follow-up study in Japan. Aliment. Pharmacol. Ther. 2005; 21: 1121-5.

11. Malfertheiner P, Megraud F, O’Morain C, et al: Current concepts in the management of Helicobacter pylori infection – the Maastricht 2–2000 Consensus Report. Aliment Pharmacol Ther. 2002; 16: 167–80.

12. Moss S, Sood: Helicobacter pylori. Curr Opin Infect Dis. 2003; 16:445-451.

13. Peek R, Blaser M: Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer. 2002; 2:28-37.

14. Peek R, Crabtree J: Helicobacter infection and gastric neoplasia. J Pathol 2006; 208:233-248

15. Romero-Gallo J, Harris E, Krishna U; Washington M, Perez G, Peek R: Effect of Helicobacter pylori Eradication on Gastric Carcinogenesis. Lab Invest. 2008; 88(3):328-336.

16. Take S, Mizuno M, Ishiki K, et al. The effect of eradicating Helicobacter pylori on the development of gastric cancer in patients with peptic ulcer disease. Am J Gastroenterol. 2005; 100: 1037–1042.

17. Uemura N, Okamoto S, Yamamoto S et al: Helicobacter pylori infection and the development of gastric cancer. New. Engl. J. Med. 2001; 345: 784-789.

18. Wang C, Yuan Y, Hunt R: The Association between Helicobacter pylori Infection and Early Gastric Cancer: A Meta-Analysis. Am J Gastroenterol. 2007; 102(8):1789-1798.

19. Warren JR, Marshall B: Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet. 1983; 1: 1273-1275.

20. Yeoh K: How Do We Improve Outcomes for Gastric Cancer? Gastroenterol Hepatol. 2007; 22(7):970-972.

21. You W, Brown L, Zhang L, et al: Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst. 2006; 98: 974–983.

22. Zagari R, Bazzoli F: Gastric cancer: who is at risk? Dig Dis. 2004; 22: 302–305.